Galen Second Read
Overview
Galen™ Second Read™, now known as Ibex Prostate Detect in the US, is a software-only device developed by Ibex Medical Analytics. It is designed to analyze scanned histopathology whole slide images (WSIs) from prostate core needle biopsies (PCNB) prepared from hematoxylin & eosin (H&E) stained formalin-fixed paraffin embedded (FFPE) tissue. The tool’s primary purpose is to identify cases initially diagnosed as benign for further review by a pathologist.
Utilizing advanced AI algorithms, Galen™ Second Read™ detects tissue morphology suspicious for prostate adenocarcinoma (AdC), providing case- and slide-level alerts which include heatmaps highlighting areas likely to contain cancer. This functionality acts as a crucial safety net, assisting pathologists in ensuring accurate and timely diagnoses, enhancing diagnostic accuracy, streamlining workflows, and ultimately improving patient outcomes. The platform is deployed globally in routine clinical use, supporting pathologists in managing increasing workloads and diagnostic complexities.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered analysis of whole slide images (WSIs)
- Detection of prostate adenocarcinoma (AdC)
- Identification of potentially missed cancers
- Case- and slide-level alerts for suspicious findings
- Heatmaps to highlight areas likely to contain cancer
- Quality control system for pathology diagnoses
- Enhances diagnostic accuracy and consistency
- Streamlines pathology workflows and improves efficiency
- Cloud-hosted solution for accessibility
- Supports pathologists in managing increasing diagnostic workloads
Use Cases
- Second read system for prostate cancer diagnosis
- Quality control in pathology laboratories
- Assisting pathologists in identifying small and rare prostatic cancers
- Improving diagnostic accuracy and consistency in prostate biopsies
- Reducing turnaround times for prostate cancer diagnosis
- Empowering pathologists to manage increasing diagnostic workloads effectively
What Physicians Need to Know
Galen™ Second Read™ (Ibex Prostate Detect) is intended as a quality-control second read, not a primary diagnostic tool. Pathologists should use the system to review flagged cases and areas of interest, but the final diagnosis should be based on the pathologist's assessment and not solely on the AI output. Be aware that while the system improves sensitivity for missed cancers, there can be a slight decrease in overall specificity. Local validation remains the responsibility of the user.
The Ibex platform is designed to integrate with various digital pathology components, including whole slide imaging (WSI) scanners, image management systems (IMS), and laboratory information systems (LIS). It is currently cleared for use with the Philips Ultra Fast Scanner. Ensure your internet connection meets the minimum requirement of 20 Mbps for optimal performance.
Details
| Category | Oncology AI, Pathology AI |
| Pricing | Contact for pricing — Contact vendor for detailed pricing plans. |
| Deployment | Cloud-hosted |
| Compliance | |
| BAA Available | Yes AI-estimated |
| HIPAA Compliant | Yes AI-estimated |
| FDA Status |
Cleared AI-estimated Galen™ Second Read™ received U.S. Food and Drug Administration (FDA) 510(k) clearance (K241232) on February 10, 2025, under its current name, Ibex Prostate Detect. It is cleared as an in vitro diagnostic medical device that uses AI to generate heatmaps identifying small and rare missed prostatic cancers, serving as a safety net for pathologists. |
| Integrations | |
| EHR | Not specified |
| Specialties | Oncology, Pathology, Urology |
FDA clearance history
This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.
| Decision date | Number | Name as listed by FDA |
| 2025-01-24 | K241232 510(k) | Galen Second Read |
What the Web Says
Galen Second Read, now known as Ibex Prostate Detect in the US, is an AI-powered digital pathology solution designed to assist pathologists in detecting prostate cancer from whole slide images of biopsies. It functions as a quality control system, performing a "second read" after initial pathologist review and flagging discrepancies or potentially missed cancers. The system has received FDA 510(k) clearance and has demonstrated high accuracy in identifying cancer and distinguishing tumor grades, with studies showing it can detect cases initially missed by pathologists.
Overall: PositiveStrengths
- Acts as a safety net, identifying cancer cases potentially missed during initial pathologist review.
- Improves diagnostic accuracy and safety by providing alerts and heatmaps for cancer, Gleason scores, and other indicators.
- Increases efficiency and addresses the shortage of pathologists by streamlining the review process.
- Demonstrated high sensitivity and specificity for cancer detection in validation studies.
- Achieved a 99.6% positive predictive value for heatmap accuracy.
- Can distinguish between low-grade and high-grade tumors with high accuracy.
Limitations
- FDA clearance is specific to the stated indication and to the United States, and local validation is still required.
- May generate false-positive alerts that necessitate additional pathologist review.
- Limitations in external validation studies, such as the need for site-specific technical calibration and reporting performance at the prostate region level rather than patient level.
- Challenges remain regarding scanner variability, staining heterogeneity, rare diagnoses with limited training data, and medico-legal questions about liability when algorithms miss critical diagnoses.
- Potential for inequitable performance in under-represented patient populations.
Based on reviews from: physicianaihandbook.com, ibex-ai.com, frontiersin.org, researchgate.net, digitalpathologyassociation.org, bmj.com, pathologyai.org, aihealthindex.io, medpath.com, targetedonc.com, scilit.com, utmb.edu
Last updated: 2026-10-30
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Galen Second Read
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for Galen Second Read.
Frequently Asked Questions
Investors who backed Galen Second Read
Funded through the company that built this tool.








